{"id":7830,"date":"2023-04-18T17:58:50","date_gmt":"2023-04-18T16:58:50","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=7830"},"modified":"2023-04-18T18:01:28","modified_gmt":"2023-04-18T17:01:28","slug":"ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/","title":{"rendered":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">18\/04\/2023 \u2013\u00a0AB Science annonce aujourd&rsquo;hui que l&rsquo;office des brevets du Japon a \u00e9mis un avis d&rsquo;acceptation pour un brevet relatif aux m\u00e9thodes de traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) avec sa mol\u00e9cule phare, le masitinib<\/h3>\n<h3 class=\"Default\"><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMy8wNC9BTFMtUGF0ZW50LVZGUi1WRi5wZGYmc2V0dGluZ3M9MTExMDExMTExMTExMTExMTEwMCZsYW5nPWVuLVVT#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-426dce23accc1961d648b69a6264b996.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-426dce23accc1961d648b69a6264b996 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2023\/04\/ALS-Patent-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1681837094865\" target=\"_blank\" id=\"default-btn-426dce23accc1961d648b69a6264b996\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 18\/04\/2023 \u2013\u00a0AB Science annonce aujourd&rsquo;hui que l&rsquo;office des brevets du Japon a \u00e9mis un avis d&rsquo;acceptation pour un brevet relatif aux m\u00e9thodes de traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) avec sa mol\u00e9cule phare, le masitinib [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[],"class_list":["post-7830","post","type-post","status-publish","format-standard","hentry","category-2023-fr","category-132","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T16:58:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T17:01:28+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037\",\"datePublished\":\"2023-04-18T16:58:50+00:00\",\"dateModified\":\"2023-04-18T17:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/\"},\"wordCount\":180,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2023\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/\",\"name\":\"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-04-18T16:58:50+00:00\",\"dateModified\":\"2023-04-18T17:01:28+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/","og_site_name":"AB Science","article_published_time":"2023-04-18T16:58:50+00:00","article_modified_time":"2023-04-18T17:01:28+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037","datePublished":"2023-04-18T16:58:50+00:00","dateModified":"2023-04-18T17:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/"},"wordCount":180,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2023"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/","name":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2023-04-18T16:58:50+00:00","dateModified":"2023-04-18T17:01:28+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science annonce l\u2019obtention d\u2019un brevet sur le masitinib au Japon pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique, renfor\u00e7ant ainsi la position de la soci\u00e9t\u00e9 en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle jusqu\u2019en 2037"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=7830"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7830\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=7830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=7830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=7830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}